Timing of rituximab and immunoglobulin level influence the risk of death for COVID-19 in ANCA-associated vasculitis
Open Access
- 20 February 2021
- journal article
- letter
- Published by Oxford University Press (OUP) in Rheumatology
- Vol. 60 (7), 3476-3477
- https://doi.org/10.1093/rheumatology/keab175
Abstract
Luca Quartuccio, Elena Treppo, Marco Binutti, Giulia Del Frate, Salvatore De Vita; Timing of Rituximab and immunoglobulin level influence the risk of death forThis publication has 9 references indexed in Scilit:
- Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals Of The Rheumatic Diseases, 2021
- Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction modelsRheumatology, 2020
- The impact of COVID-19 pandemic on patients with ANCA associated vasculitisJournal of Nephrology, 2020
- Response to: ‘Glucocorticoid-induced relapse of COVID-19 in a patient with sarcoidosis’ by Györfi et alAnnals Of The Rheumatic Diseases, 2020
- Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximabAnnals Of The Rheumatic Diseases, 2020
- Persisting SARS‐CoV‐2 viraemia after rituximab therapy: two cases with fatal outcome and a review of the literatureBritish Journal of Haematology, 2020
- Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registryAnnals Of The Rheumatic Diseases, 2020
- Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumoniaAnnals Of The Rheumatic Diseases, 2020
- BSR and BHPR guideline for the management of adults with ANCA-associated vasculitisRheumatology, 2014